Overview
ACADIA Pharmaceuticals Inc., based in the United States, operates primarily within the biopharmaceutical industry, focusing on the development and commercialization of medications aimed at improving the lives of patients with central nervous system disorders. The company's flagship product, Nuplazid (pimavanserine), is approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Additionally, ACADIA is involved in a range of projects targeting other CNS conditions, including schizophrenia, depression, and dementia-related psychosis. Through ongoing research and clinical trials, ACADIA strives to expand the applications of its proprietary drug, pimavanserin, while continuously exploring new therapeutic candidates to enhance its portfolio and address the unmet medical needs of CNS patients.
Basic Stats
The share price of ACADIA Pharmaceuticals Inc. as of September 5, 2025 is $25.26 / share. This is a decrease of -2.81% from the prior week. The market cap (or net worth) of ACADIA Pharmaceuticals Inc. as of September 5, 2025 is $4,239.31 MM.
The Factor Analysis chart (below right) shows a view of ACADIA Pharmaceuticals Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 4,239.31 MM |
| EV | 3,477.31 MM |
| Shares Out. | 167.83 MM |
| Earnings Date | |
| EPS (TTM) | 1.32 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.25 |
| Short Shares Avail. | 2.60 MM |
| Short Interest | 9.98 MM |
| Short Float | 8.62 % |
| Days to Cover | 7.48 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | 55.73 % |
| Volatility (1 yr) | 0.48 |
| Beta | 1.25 |
| Sharpe Ratio (1 yr) | 1.07 |
| Sortino Ratio (1 yr) | 2.53 |
| PE Ratio | 19.08 |
| Price/Book | 5.15 |
| Price/TBV | 5.99 |
| Book/Market | 0.19 |
| EBIT/EV | 0.08 |
| EBIT(3yr avg)/EV | 0.02 |
| ROA | 0.24 |
| ROE | 0.43 |
| ROIC | 0.25 |
| CROIC | 0.09 |
| OCROIC | 0.21 |
| Implied Volatility | 49.35 % |
| Put/Call OI Ratio | 0.69 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for ACADIA Pharmaceuticals Inc. is $30.32. The forecasts range from a low of $17.17 to a high of $42.00. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for ACADIA Pharmaceuticals Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2022-12-21 | Mizuho | Neutral | Maintains | |
| 2022-11-14 | JP Morgan | Neutral | Maintains | |
| 2022-11-04 | Goldman Sachs | Neutral | Sell | Downgrade |
| 2022-11-03 | RBC Capital | Outperform | Maintains | |
| 2022-11-01 | Loop Capital | Hold | Initiate | |
| 2022-08-10 | Mizuho | Neutral | Maintains | |
| 2022-08-10 | Goldman Sachs | Neutral | Maintains | |
| 2022-08-09 | SVB Leerink | Outperform | Maintains | |
| 2022-08-09 | RBC Capital | Outperform | Maintains | |
| 2022-08-09 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-08-09 | Mizuho | Neutral | Maintains | |
| 2022-08-09 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-08-09 | Goldman Sachs | Neutral | Maintains | |
| 2022-08-08 | Cowen & Co. | Outperform | Maintains | |
| 2022-08-08 | Citigroup | Buy | Neutral | Downgrade |
| 2022-08-05 | Citigroup | Buy | Neutral | Downgrade |
| 2022-07-15 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-07-11 | SVB Leerink | Outperform | Maintains | |
| 2022-06-22 | Citigroup | Buy | Maintains | |
| 2022-06-21 | RBC Capital | Outperform | Maintains | |
| 2022-06-21 | Oppenheimer | Perform | Maintains | |
| 2022-06-21 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-06-21 | Cantor Fitzgerald | Overweight | Maintains | |
| 2022-04-19 | Mizuho | Neutral | Maintains | |
| 2022-03-16 | Canaccord Genuity | Hold | Buy | Upgrade |
| 2022-03-10 | Cantor Fitzgerald | Overweight | Maintains | |
| 2022-03-07 | Goldman Sachs | Neutral | Maintains | |
| 2022-03-03 | Mizuho | Neutral | Maintains | |
| 2022-03-01 | JMP Securities | Market Outperform | Maintains | |
| 2022-02-09 | HC Wainwright & Co. | Neutral | Buy | Upgrade |
| 2022-01-05 | Citigroup | Neutral | Buy | Upgrade |
| 2021-12-22 | Canaccord Genuity | Hold | Maintains | |
| 2021-12-21 | RBC Capital | Outperform | Maintains | |
| 2021-12-21 | JMP Securities | Market Outperform | Maintains | |
| 2021-12-21 | Guggenheim | Buy | Neutral | Downgrade |
| 2021-12-21 | Citigroup | Neutral | Maintains | |
| 2021-12-21 | B of A Securities | Neutral | Maintains | |
| 2021-12-09 | Oppenheimer | Perform | Maintains | |
| 2021-12-09 | JMP Securities | Market Outperform | Maintains | |
| 2021-12-08 | Goldman Sachs | Neutral | Maintains | |
| 2021-12-07 | Oppenheimer | Perform | Maintains | |
| 2021-12-07 | Morgan Stanley | Equal-Weight | Maintains | |
| 2021-12-07 | Mizuho | Neutral | Maintains | |
| 2021-12-07 | JMP Securities | Market Outperform | Maintains | |
| 2021-12-07 | Citigroup | Neutral | Maintains | |
| 2021-11-01 | Guggenheim | Neutral | Buy | Upgrade |
| 2021-10-14 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2021-08-05 | SVB Leerink | Outperform | Maintains | |
| 2021-08-05 | Needham | Buy | Maintains | |
| 2021-08-05 | Morgan Stanley | Overweight | Maintains | |
| 2021-06-10 | Berenberg | Hold | Initiate | |
| 2021-05-12 | Canaccord Genuity | Hold | Maintains | |
| 2021-05-06 | Morgan Stanley | Overweight | Maintains | |
| 2021-04-07 | HC Wainwright & Co. | Buy | Neutral | Downgrade |
| 2021-04-06 | Morgan Stanley | Overweight | Maintains | |
| 2021-04-06 | Mizuho | Buy | Neutral | Downgrade |
| 2021-04-06 | Jefferies | Buy | Hold | Downgrade |
| 2021-04-06 | Goldman Sachs | Buy | Neutral | Downgrade |
| 2021-04-06 | Canaccord Genuity | Buy | Hold | Downgrade |
| 2021-04-05 | Needham | Buy | Maintains | |
| 2021-03-10 | B of A Securities | Buy | Neutral | Downgrade |
| 2021-03-09 | Stifel | Buy | Hold | Downgrade |
| 2021-03-09 | Raymond James | Strong Buy | Outperform | Downgrade |
| 2021-03-09 | Needham | Buy | Maintains | |
| 2021-03-09 | Morgan Stanley | Overweight | Maintains | |
| 2021-03-09 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-03-09 | Guggenheim | Buy | Neutral | Downgrade |
| 2021-03-09 | Citigroup | Buy | Neutral | Downgrade |
| 2021-03-09 | Canaccord Genuity | Buy | Maintains | |
| 2021-02-25 | Morgan Stanley | Overweight | Maintains | |
| 2020-12-16 | Morgan Stanley | Overweight | Maintains | |
| 2020-12-16 | Mizuho | Buy | Initiate | |
| 2020-11-16 | Raymond James | Outperform | Strong Buy | Upgrade |
| 2020-11-05 | Morgan Stanley | Overweight | Maintains | |
| 2020-10-13 | Morgan Stanley | Overweight | Maintains | |
| 2020-08-25 | Raymond James | Outperform | Initiate | |
| 2020-08-20 | Morgan Stanley | Overweight | Initiate | |
| 2020-08-06 | SVB Leerink | Outperform | Maintains | |
| 2020-08-06 | Canaccord Genuity | Buy | Maintains | |
| 2020-07-21 | RBC Capital | Outperform | Maintains | |
| 2020-07-21 | Oppenheimer | Perform | Maintains | |
| 2020-07-21 | Cantor Fitzgerald | Overweight | Maintains | |
| 2020-07-07 | Stifel | Hold | Buy | Upgrade |
| 2020-05-27 | Oppenheimer | Perform | Maintains | |
| 2020-05-08 | JP Morgan | Overweight | Maintains | |
| 2020-05-08 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2020-04-16 | Jefferies | Buy | Initiate | |
| 2020-03-31 | Goldman Sachs | Neutral | Buy | Upgrade |
| 2020-03-06 | Citigroup | Buy | Initiate | |
| 2020-03-02 | JP Morgan | Neutral | Maintains | |
| 2020-02-27 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2019-12-16 | Guggenheim Securities | Buy | Initiate | |
| 2019-11-26 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2019-11-07 | JP Morgan | Neutral | Maintains | |
| 2019-10-24 | Oppenheimer | Perform | Initiate | |
| 2019-10-01 | RBC Capital | Outperform | Initiate | |
| 2019-09-23 | Cantor Fitzgerald | Overweight | Maintains | |
| 2019-09-13 | SVB Leerink | Market Perform | Outperform | Upgrade |
| 2019-09-10 | Canaccord Genuity | Hold | Buy | Upgrade |
| 2019-09-09 | Needham | Buy | Maintains | |
| 2019-09-03 | Stifel Nicolaus | Hold | Maintains | |
| 2019-08-27 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2019-05-31 | Raymond James | Strong Buy | Reiterate | |
| 2018-12-10 | Canaccord Genuity | Hold | Initiate | |
| 2018-11-16 | UBS | Neutral | Initiate | |
| 2018-11-15 | Leerink Swann | Market Perform | Initiate | |
| 2018-11-13 | Leerink Swann | Market Perform | Initiate | |
| 2018-11-01 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2018-10-16 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2018-10-10 | Bank of America | Buy | Buy | Maintains |
| 2018-09-21 | PiperJaffray | Neutral | Overweight | Upgrade |
| 2018-08-23 | Cantor Fitzgerald | Overweight | Initiate | |
| 2018-08-09 | Stifel Nicolaus | Hold | Hold | Maintains |
| 2018-08-09 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2018-08-07 | Stifel Nicolaus | Hold | Initiate | |
| 2018-08-06 | PiperJaffray | Overweight | Neutral | Downgrade |
| 2016-11-11 | Goldman Sachs | Neutral | Initiate | |
| 2016-11-08 | Bank of America | Neutral | Buy | Upgrade |
| 2016-10-04 | Leerink Swann | Market Perform | Initiate | |
| 2016-06-22 | Bank of America | Buy | Neutral | Downgrade |
| 2016-05-03 | Leerink Swann | Outperform | Market Perform | Downgrade |
| 2016-02-24 | JP Morgan | Neutral | Maintains | |
| 2016-02-08 | Bank of America | Buy | Initiate | |
| 2016-01-22 | PiperJaffray | Neutral | Overweight | Upgrade |
| 2015-11-06 | Leerink Swann | Outperform | Maintains | |
| 2015-08-07 | PiperJaffray | Overweight | Neutral | Downgrade |
| 2015-08-07 | JP Morgan | Overweight | Maintains | |
| 2015-05-08 | JP Morgan | Overweight | Maintains | |
| 2015-04-16 | Leerink Swann | Outperform | Initiate | |
| 2015-03-12 | Jefferies | Buy | Maintains | |
| 2015-02-27 | JMP Securities | Market Outperform | Maintains | |
| 2015-02-24 | H.C. Wainwright | Buy | Initiate | |
| 2015-01-28 | Jefferies | Buy | Maintains | |
| 2014-11-21 | Cowen & Co. | Outperform | Initiate | |
| 2014-05-15 | JP Morgan | Overweight | Initiate | |
| 2013-08-07 | McNicoll Lewis Vlak | Buy | Hold | Downgrade |
| 2013-06-14 | JMP Securities | Market Outperform | Maintains | |
| 2013-04-12 | Jefferies | Buy | Maintains | |
| 2013-04-11 | Roth Capital | Buy | Maintains | |
| 2013-04-11 | PiperJaffray | Neutral | Overweight | Upgrade |
| 2013-04-11 | McNicoll Lewis Vlak | Buy | Maintains | |
| 2013-03-25 | McNicoll Lewis Vlak | Buy | Maintains | |
| 2013-03-19 | Jefferies | Buy | Initiate | |
| 2013-01-28 | Cowen & Co. | Outperform | Initiate | |
| 2012-11-27 | Needham | Hold | Buy | Upgrade |
| 2012-04-30 | Ladenburg Thalmann | Buy | Initiate | |
| 2023-01-31 | Citigroup | Neutral | Maintains | |
| 2023-02-15 | Oppenheimer | Perform | Maintains | |
| 2023-02-28 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-02-28 | RBC Capital | Outperform | Maintains | |
| 2023-02-28 | Citigroup | Neutral | Maintains | |
| 2023-02-28 | JMP Securities | Market Perform | Maintains | |
| 2023-02-28 | Morgan Stanley | Equal-Weight | Maintains | |
| 2023-02-28 | Mizuho | Neutral | Maintains | |
| 2023-03-01 | Oppenheimer | Perform | Maintains | |
| 2023-01-03 | Guggenheim | Neutral | Buy | Upgrade |
| 2023-03-14 | RBC Capital | Outperform | Reiterate | |
| 2023-03-14 | Cantor Fitzgerald | Overweight | Maintains | |
| 2023-03-14 | Canaccord Genuity | Buy | Maintains | |
| 2023-03-14 | Citigroup | Neutral | Maintains | |
| 2023-03-14 | HC Wainwright & Co. | Buy | Maintains | |
| 2023-03-13 | Mizuho | Neutral | Reiterate | |
| 2023-03-14 | Morgan Stanley | Equal-Weight | Maintains | |
| 2023-03-20 | JP Morgan | Neutral | Maintains | |
| 2023-05-09 | RBC Capital | Outperform | Reiterate | |
| 2023-05-09 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2023-04-14 | Mizuho | Neutral | Reiterate | |
| 2023-05-22 | B of A Securities | Neutral | Neutral | Maintains |
| 2023-05-09 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-05-09 | JMP Securities | Outperform | Maintains | |
| 2023-05-09 | Citigroup | Neutral | Maintains | |
| 2023-06-14 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-06-14 | Mizuho | Neutral | Neutral | Reiterate |
| 2023-06-14 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2024-05-09 | Citigroup | Buy | Buy | Maintains |
| 2024-05-09 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2023-11-03 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2024-03-25 | JP Morgan | Overweight | Overweight | Maintains |
| 2023-08-22 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-07-28 | Oppenheimer | Perform | Perform | Maintains |
| 2023-07-17 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2023-12-18 | Stifel | Hold | Hold | Maintains |
| 2024-01-24 | Needham | Hold | Buy | Upgrade |
| 2023-12-13 | Citigroup | Buy | Initiate | |
| 2023-11-03 | RBC Capital | Outperform | Outperform | Maintains |
| 2023-11-03 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2023-07-11 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2023-10-17 | UBS | Buy | Initiate | |
| 2023-08-07 | JP Morgan | Neutral | Neutral | Maintains |
| 2023-08-03 | Morgan Stanley | Equal-Weight | Equal-Weight | Reiterate |
| 2023-08-03 | Canaccord Genuity | Buy | Buy | Maintains |
| 2023-12-19 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| 2023-08-03 | Oppenheimer | Perform | Perform | Reiterate |
| 2023-08-03 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-12-14 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-12-14 | Deutsche Bank | Buy | Hold | Downgrade |
| 2024-03-13 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2023-07-14 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2023-07-14 | Citigroup | Neutral | Neutral | Maintains |
| 2023-07-14 | RBC Capital | Outperform | Outperform | Maintains |
| 2023-07-14 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2023-07-14 | Oppenheimer | Perform | Perform | Maintains |
| 2023-07-14 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2023-10-10 | JP Morgan | Neutral | Overweight | Upgrade |
| 2023-11-06 | Mizuho | Neutral | Buy | Upgrade |
| 2023-12-12 | Deutsche Bank | Buy | Initiate | |
| 2024-02-02 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-02-28 | Needham | Buy | Buy | Maintains |
| 2024-01-30 | Baird | Outperform | Initiate | |
| 2024-02-05 | Oppenheimer | Perform | Perform | Reiterate |
| 2024-05-10 | B of A Securities | Neutral | Neutral | Maintains |
| 2024-02-28 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-02-28 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-02-28 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-02-28 | Mizuho | Buy | Buy | Maintains |
| 2024-03-12 | Citigroup | Buy | Buy | Maintains |
| 2024-03-12 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-03-12 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2024-03-12 | Oppenheimer | Perform | Perform | Maintains |
| 2024-03-12 | Baird | Outperform | Outperform | Maintains |
| 2024-03-12 | B of A Securities | Neutral | Neutral | Maintains |
| 2024-03-12 | Canaccord Genuity | Buy | Buy | Maintains |
| 2024-03-12 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-03-12 | JMP Securities | Outperform | Outperform | Maintains |
| 2024-03-12 | Mizuho | Buy | Neutral | Downgrade |
| 2024-03-12 | Needham | Buy | Buy | Maintains |
| 2024-02-07 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-05-06 | Oppenheimer | Perform | Perform | Maintains |
| 2024-04-10 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-03-01 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-04-09 | Needham | Buy | Buy | Reiterate |
| 2023-12-29 | Mizuho | Buy | Buy | Maintains |
| 2024-04-30 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-05-09 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-05-09 | Stifel | Hold | Hold | Maintains |
| 2024-05-09 | Mizuho | Neutral | Neutral | Maintains |
| 2024-05-09 | Baird | Outperform | Outperform | Maintains |
| 2024-05-09 | Needham | Buy | Buy | Reiterate |
| 2024-07-12 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2024-06-25 | RBC Capital | Outperform | Outperform | Reiterate |
| 2024-06-27 | BMO Capital | Outperform | Initiate | |
| 2024-08-07 | Needham | Buy | Buy | Maintains |
| 2024-08-07 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-08-07 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2024-08-07 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2025-02-27 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2025-02-27 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-02-27 | Needham | Buy | Buy | Reiterate |
| 2024-08-08 | Citigroup | Buy | Buy | Maintains |
| 2024-08-08 | UBS | Buy | Buy | Maintains |
| 2024-08-08 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-02-11 | Deutsche Bank | Hold | Initiate | |
| 2024-11-07 | Needham | Buy | Buy | Reiterate |
| 2024-11-07 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-01-03 | Guggenheim | Buy | Neutral | Downgrade |
| 2024-10-10 | Raymond James | Market Perform | Reiterate | |
| 2025-04-08 | Needham | Buy | Buy | Reiterate |
| 2025-08-08 | UBS | Buy | Buy | Maintains |
| 2025-04-28 | UBS | Buy | Buy | Maintains |
| 2025-05-19 | BMO Capital | Outperform | Outperform | Maintains |
| 2025-05-19 | Mizuho | Neutral | Neutral | Maintains |
| 2025-05-19 | RBC Capital | Outperform | Outperform | Reiterate |
| 2025-05-19 | Baird | Outperform | Outperform | Maintains |
| 2025-06-26 | Oppenheimer | Perform | Perform | Maintains |
| 2025-05-19 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-05-19 | Needham | Buy | Buy | Maintains |
| 2025-07-24 | JP Morgan | Overweight | Overweight | Maintains |
| 2025-08-07 | Goldman Sachs | Sell | Sell | Maintains |
| 2025-08-07 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-08-07 | Mizuho | Neutral | Neutral | Maintains |
| 2025-08-07 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2025-06-05 | B of A Securities | Neutral | Neutral | Maintains |
| 2025-06-26 | Needham | Buy | Buy | Reiterate |
| 2025-06-26 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-06-06 | JP Morgan | Overweight | Overweight | Maintains |
| 2025-05-20 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2025-06-26 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2025-06-23 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-05-21 | Deutsche Bank | Hold | Buy | Upgrade |
